MET and Miyoshi myopathy: Cabozantinib, which is FDA-approved for medullary thyroid cancer and renal cell carcinoma, is yet another oral ATP-competitive MET inhibitor; it is now under clinical study for relapsed/refractory MM (NCT01866293).